Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Novo Nordisk has launched its weight-loss drug Wegovy in India, while Eli Lilly's Mounjaro has received regulatory approval, ...

She began using Wegovy, the version of Ozempic approved for weight loss, after struggling with obesity. She reveals which ...

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

With the weight-loss blockbuster drug Wegovy, now in India, renowned endocrinologist and diabetologist Dr. Ambrish Mithal ...

Danish pharma giant Novo Nordisk’s announcement comes months after the launch of another top selling obesity drug Mounjaro in India by US based pharma giant Eli Lilly & Company.

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Eli Lilly's orforglipron reduced A1C and weight in type 2 diabetes, while weekly insulin efsitora matched daily insulin with ...

The blockbuster weight loss drug, semaglutide, now has competition in orforglipron, which is just as safe as injectable ...

A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control ...